Bal Pharma

{
  "main_header": {
    "sid": 555664,
    "name": "Bal Pharma",
    "stock_name": "Bal Pharma",
    "full_name": "Bal Pharma Ltd",
    "name_url": "stocks-analysis/bal-pharma",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "65.25",
    "chg": -1.68,
    "chgp": "-2.51%",
    "dir": -1,
    "prev_price": "66.93",
    "mcapval": "105.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524824,
    "symbol": "BALPHARMA",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE083D01012",
    "curr_date": "Mar 27",
    "curr_time": "",
    "bse_nse_vol": "60.61 k",
    "exc_status": "Active",
    "traded_date": "Mar 27, 2026",
    "traded_date_str": "2026 03 27",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/bal-pharma-555664-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Bal Pharma Ltd Falls to 52-Week Low of Rs 64 as Sell-Off Deepens",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bal-pharma-ltd-falls-to-52-week-low-amidst-weak-market-and-fundamental-pressures-3920090",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/BalPharmaLtd_priceRelatedfactors_3920090.png",
        "date": "2026-03-27 15:05:10",
        "description": "For the fifth consecutive session, Bal Pharma Ltd closed lower, slipping to a fresh 52-week low of Rs 64 on 27 Mar 2026. This decline comes amid a broader market downturn, but the stock’s underperformance remains pronounced compared to its sector and benchmark indices."
      },
      {
        "title": "Bal Pharma Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/bal-pharma-ltd-is-rated-strong-sell-3918904",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/BalPharmaLtd_mojoScore_3918904.png",
        "date": "2026-03-27 10:10:27",
        "description": "Bal Pharma Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 28 May 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 27 March 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Bal Pharma Ltd Falls to 52-Week Low Amid Continued Downtrend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bal-pharma-ltd-falls-to-52-week-low-amid-continued-downtrend-3897007",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/BalPharmaLtd_priceRelatedfactors_3897007.png",
        "date": "2026-03-17 16:01:09",
        "description": "Bal Pharma Ltd’s shares have declined to within 3.03% of their 52-week low, marking a significant downturn for the micro-cap pharmaceutical company. The stock closed near Rs 66, approaching its lowest price point of Rs 64 over the past year, reflecting ongoing pressures in its market performance and fundamentals."
      },
      {
        "title": "Bal Pharma Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/bal-pharma-ltd-is-rated-strong-sell-3892098",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/BalPharmaLtd_mojoScore_3892098.png",
        "date": "2026-03-15 10:10:23",
        "description": "Bal Pharma Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 28 May 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 15 March 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Bal Pharma Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/bal-pharma-ltd-is-rated-strong-sell-3866193",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/BalPharmaLtd_mojoScore_3866193.png",
        "date": "2026-03-03 10:10:34",
        "description": "Bal Pharma Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 03 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Bal Pharma Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/bal-pharma-ltd-is-rated-strong-sell-3848078",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/BalPharmaLtd_mojoScore_3848078.png",
        "date": "2026-02-20 10:10:49",
        "description": "Bal Pharma Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 20 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Why is Bal Pharma Ltd falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-bal-pharma-ltd-fallingrising-3838721",
        "imagepath": "",
        "date": "2026-02-14 01:12:11",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Context</strong></p>\n<p>Bal Pharma Ltd has demonstrated a robust performance over the past week, gaining 8.70% while the Sensex declined by 1.14%. This divergence highlights the stock’s relative strength amid broader market weakness. Over the last month, the stock has appreciated by 6.37%, again contrasting with the Sensex’s 1.20% decline. Year-to-date, Bal Pharma has delivered a positive return of 3.21%, whereas the benchmark index has fallen by 3.04%. These figures indicate that the stock is currently benefiting from favourable investor sentiment and momentum, despite its longer-term underperformance.</p>\n<p>It is important to note that over a one-year horizon, Bal Pharma’s stock has declined by 25.19%, significantly lagging the Sensex’s 8.52% gain. Similar..."
      },
      {
        "title": "Are Bal Pharma Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-bal-pharma-ltd-latest-results-good-or-bad-3835689",
        "imagepath": "",
        "date": "2026-02-12 19:44:56",
        "description": "Bal Pharma Ltd's latest financial results for the quarter ended December 2025 reveal a complex picture of performance. The company reported net sales of ₹87.69 crores, marking a year-on-year growth of 19.88%, a notable recovery from a previous decline. This revenue growth is the highest quarterly figure recorded by the company, indicating potential improvements in demand or market positioning.\n\nHowever, despite this top-line growth, the operational efficiency remains a concern. The operating margin, which stands at 10.89%, has only marginally improved from the previous year, suggesting persistent cost pressures and pricing challenges that are impacting profitability. The profit after tax (PAT) of ₹1.78 crores reflects a dramatic year-on-year increase of 270.83%, but this figure is modest in absolute terms relative to the company's revenue.\n\nThe financial metrics also highlight ongoing challenges with capita..."
      },
      {
        "title": "Bal Pharma Q3 FY26: Strong Quarter Masks Deeper Structural Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/bal-pharma-q3-fy26-strong-quarter-masks-deeper-structural-concerns-3835138",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/BalPharma_quaterlyResult_3835138.png",
        "date": "2026-02-12 09:41:23",
        "description": "Bal Pharma Ltd., a Bangalore-based pharmaceutical manufacturer and member of the Micro Laboratories Group, reported consolidated net profit of ₹1.78 crores for Q3 FY26 (October-December 2025), marking a dramatic 270.83% year-on-year surge from ₹0.48 crores in Q3 FY25. The micro-cap pharmaceutical company, with a market capitalisation of ₹121.00 crores, saw its stock surge 6.79% to ₹75.82 following the results announcement, though the shares remain 41.16% below their 52-week high of ₹128.86."
      }
    ],
    "total": 131,
    "sid": "555664",
    "stock_news_url": "https://www.marketsmojo.com/news/bal-pharma-555664"
  },
  "announcements": [
    {
      "caption": "Closure of Trading Window",
      "datetime": "23-Mar-2026",
      "details": "Closure of Trading Window for the quarter and financial year ended 31.03.2026.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "16-Feb-2026",
      "details": "Newspaper publication of Unaudited financial results for the quarter ended 31.12.2025.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of The Board Meeting_ Standalone And Consolidated Financial Results For The Quarter Ended 31.12.2025.",
      "datetime": "11-Feb-2026",
      "details": "Unaudited standalone and consolidated financial results for the quarter ended 31.12.2025.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Bal Pharma Ltd has declared <strong>12%</strong> dividend, ex-date: 18 Sep 25",
          "dt": "2025-09-18",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Bal Pharma Ltd Falls to 52-Week Low of Rs 64 as Sell-Off Deepens

2026-03-27 15:05:10

For the fifth consecutive session, Bal Pharma Ltd closed lower, slipping to a fresh 52-week low of Rs 64 on 27 Mar 2026. This decline comes amid a broader market downturn, but the stock’s underperformance remains pronounced compared to its sector and benchmark indices.

Read full news article

Bal Pharma Ltd is Rated Strong Sell

2026-03-27 10:10:27

Bal Pharma Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 28 May 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 27 March 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

Bal Pharma Ltd Falls to 52-Week Low Amid Continued Downtrend

2026-03-17 16:01:09

Bal Pharma Ltd’s shares have declined to within 3.03% of their 52-week low, marking a significant downturn for the micro-cap pharmaceutical company. The stock closed near Rs 66, approaching its lowest price point of Rs 64 over the past year, reflecting ongoing pressures in its market performance and fundamentals.

Read full news article

Bal Pharma Ltd is Rated Strong Sell

2026-03-15 10:10:23

Bal Pharma Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 28 May 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 15 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Bal Pharma Ltd is Rated Strong Sell

2026-03-03 10:10:34

Bal Pharma Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 03 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Bal Pharma Ltd is Rated Strong Sell

2026-02-20 10:10:49

Bal Pharma Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 20 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Why is Bal Pharma Ltd falling/rising?

2026-02-14 01:12:11

Recent Price Movement and Market Context

Bal Pharma Ltd has demonstrated a robust performance over the past week, gaining 8.70% while the Sensex declined by 1.14%. This divergence highlights the stock’s relative strength amid broader market weakness. Over the last month, the stock has appreciated by 6.37%, again contrasting with the Sensex’s 1.20% decline. Year-to-date, Bal Pharma has delivered a positive return of 3.21%, whereas the benchmark index has fallen by 3.04%. These figures indicate that the stock is currently benefiting from favourable investor sentiment and momentum, despite its longer-term underperformance.

It is important to note that over a one-year horizon, Bal Pharma’s stock has declined by 25.19%, significantly lagging the Sensex’s 8.52% gain. Similar...

Read full news article

Are Bal Pharma Ltd latest results good or bad?

2026-02-12 19:44:56

Bal Pharma Ltd's latest financial results for the quarter ended December 2025 reveal a complex picture of performance. The company reported net sales of ₹87.69 crores, marking a year-on-year growth of 19.88%, a notable recovery from a previous decline. This revenue growth is the highest quarterly figure recorded by the company, indicating potential improvements in demand or market positioning. However, despite this top-line growth, the operational efficiency remains a concern. The operating margin, which stands at 10.89%, has only marginally improved from the previous year, suggesting persistent cost pressures and pricing challenges that are impacting profitability. The profit after tax (PAT) of ₹1.78 crores reflects a dramatic year-on-year increase of 270.83%, but this figure is modest in absolute terms relative to the company's revenue. The financial metrics also highlight ongoing challenges with capita...

Read full news article

Bal Pharma Q3 FY26: Strong Quarter Masks Deeper Structural Concerns

2026-02-12 09:41:23

Bal Pharma Ltd., a Bangalore-based pharmaceutical manufacturer and member of the Micro Laboratories Group, reported consolidated net profit of ₹1.78 crores for Q3 FY26 (October-December 2025), marking a dramatic 270.83% year-on-year surge from ₹0.48 crores in Q3 FY25. The micro-cap pharmaceutical company, with a market capitalisation of ₹121.00 crores, saw its stock surge 6.79% to ₹75.82 following the results announcement, though the shares remain 41.16% below their 52-week high of ₹128.86.

Read full news article

View All News